PL EN


Preferences help
enabled [disable] Abstract
Number of results
2019 | 130 | 71-81
Article title

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency – management and differentiation in adults

Authors
Content
Title variants
Languages of publication
EN
Abstracts
EN
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive hereditary diseases. The lack of cortisol synthesis leads to excessive stimulation of the adrenal glands by adrenocorticotropic hormone (ACTH). Moreover the impairment of cortisol synthesis results in adrenal hyperplasia and excessive androgen synthesis. Congenital adrenal hyperplasia is characterised by a considerable correlation between the genotype and the phenotype with the type of CYP21A2 gene mutation affecting the severity of 21-hydroxylase deficiency. The clinical manifestations of congenital adrenal hyperplasia in adults result from adrenocortical insufficiency, hyperandrogenism, and the adverse effects of glucocorticosteroids, which are used for the treatment of the syndrome. Non-classic congenital adrenal hyperplasia may sometimes have no clinical manifestation. Patients with classic congenital adrenal hyperplasia experience a wide variety of symptoms, including obesity, hypertension, hyperinsulinaemia, insulin resistance, and hyperleptinaemia. These abnormalities, the same as glucocorticosteroid treatment, promote the development of other diseases, such as metabolic syndrome, diabetes mellulitis, cardiovascular diseases and psychosocial problems. Moreover glucocorticosteroids treatment increases risk of osteoporosis and dermatological disorders. The maladies are more often seen in patients suffering from congenital adrenal hyperplasia syndrome than in the general population. Patients suffering from congenital adrenal hyperplasia require systematic evaluation of biochemical parameters (17-hydroxyprogesterone and androstendion) the same as clinical parameters (body mass index, waist circumference, glucose, lipids, blood pressure). Medical care for patients suffering from congenital adrenal hyperplasia should be provided by reference centres. Patients require cooperation between an endocrinologist, diabetologist, gynaecologist, andrologist, urologist, sexuologist and psychologist.
Discipline
Year
Volume
130
Pages
71-81
Physical description
Contributors
author
  • Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland
References
  • [1] Urszula Ambroziak, Tomasz Bednarczuk et al.; Congenital adrenal hyperplasia due to 21-hydroxylase deficiency — management in adults. Polish Journal of Endocrinology 2010; 61(1): 142-145
  • [2] Fardella CE, et al.; Salt-wasting congenital adrenal hyperplasia: detection of mutations in CYP21B gene in a Chilean population. J Clin Endocrinol Metab, 1998 Sep; 83(9): 3357-60
  • [3] White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Rev 2000; 21: 245-291
  • [4] Pang SY, Wallace MA, Hofman L, et al., Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 81: 866
  • [5] Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349: 776
  • [6] Pang S, Clark A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993; 2: 105-139
  • [7] Therrell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30: 15
  • [8] Lee HH, Kuo JM, Chao HT, et al., Carrier analysis and prenatal diagnosis of congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in Chinese. J Clin Endocrinol Metab 2000; 85: 597
  • [9] New MI, White PC. Genetic disorders of steroid hormone synthesis and metabolism. Baillieres Clin Endocrinol Metab 1995; 9: 525
  • [10] Cutfield WS, Webster D. Newborn screening for congenital adrenal hyperplasia in New Zealand. J Pediatr 1995; 126: 118
  • [11] Pang S, Murphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 55: 413
  • [12] Speiser PW, Dupont J, Zhu D et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992; 90: 584-595
  • [13] Therrell BL Jr, Berenbaum SA, Manter-Kapanke V et al., Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998; 101: 583
  • [14] Ferenczi A, Garami M, Kiss E, et al. Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999; 84: 2369
  • [15] Tiitinen A, Valimaki M, Primary infertility in 45-year-old man with untreated 21-hydroxylase deficiency: successful outcome with glucocorticoid therapy. J Clin Endocrinol Metab 2002; 87: 2442
  • [16] Waad-Allah S. Mula-Abed, et al., Congenital Adrenal Hyperplasia due to 17-alpha-hydoxylase/17,20-lyase Deficiency Presenting with Hypertension and Pseudohermaphroditism: First Case Report from Oman. Oman Med J, 2014 Jan; 29(1): 55-59
  • [17] Biglieri EG, Herron MA, Brust N, 17-hydroxylation deficiency in man. J Clin Invest 1966; 45: 1946
  • [18] Merke DP, Bornstein SR., Congenital adrenal hyperplasia. Lancet 2005; 365: 2125
  • [19] Speiser PW, Azziz R, Baskin LS, et al., Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guide. J Clin Endocrinol Metab 2010; 95: 4133
  • [20] Merke DP, Chrousos GP, Esenhofer G et al., Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 2000; 343: 1362-1368
  • [21] Merke DP, Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2008; 93: 653-660
  • [22] S. Sachdera, Hirsutism evaluation and treatment. Indian J Dermatol, 2010 Jan Mar; 55(1): 3-7
  • [23] R. L. Rosenfield, Pilosebaceous physiology in relation to hirsutism and acne. Clin Endocrinol Metab 15: 341-362, 1986
  • [24] Yohei Tanaka et al., Adrogenetic Alopecia Treatment in Asian Men. J Clin Aesthet Dermatol 2018 Jul; 11(7): 32-35
  • [25] Słowińska M, Rudnicka L, 35-year old woman with excessive hair loss. Practice Medicine 2013.
  • [26] Lo JC, Grumbach MM, Pregnancy outcomes in women with congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30: 2017-229
  • [27] Barnes RB, Rosenfield RL, Ehrmann DA et al., Ovarian hyperandrogenism as a result of congenital adrenal virilising disorders: evidence for perinatal masculinization of neuroendocrine function in woman. J Clin Endocrinol Metab 1994; 79: 1328-1333
  • [28] Ogilvie CM, Croucht NS, Rumbsy F et al., Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. Clin Endocrinol Metab 2006; 64: 2-11
  • [29] Wilkins L, Cara J. Further studies on the treatment of congenital adrenal hyperplasia with cortisone: Effects of cortisone treatment on testicular development. J Clin Endocinol Metab 1954; 14: 287-296
  • [30] Reich N, Flade L Scherr M et al., High prevalence of reduced fecundity in man with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009; 94: 1665-1670
  • [31] Moran C, Azziz R, Carmina E et al., 21-hydroxylase deficient nonclassical adrenal hyperplasia in a progressive disorder: a multicenter study. Am J Ostet Gynecol 2000; 183: 1468-1474
  • [32] Jaresch S, Kornely E, Kley HK et al., Adrenal incidentaloma and patients with homozygous and heterozygous congenital adrenal yperplasia. J Clin Endocrinol Metab 1992; 74: 685-689
  • [33] Eugster EA, Dimeglio LA, Wright JC et al., Hight outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a metaanalysis. J Pediatr 2001; 138: 26-32
  • [34] Falhammer H, Filipsson H, Holmdahl G et al., Fractures and bone mineral density in adult woman with 21-hydroxylase deficiency, J Clin Endorinol Metab 2007; 92: 4643-4649
  • [35] Stikkelbroeck NM, Oyen WJ, van der Wilt GJ et al., Normal bone mineral density and lean body mass, but increased fat mass in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88: 1036-1042
  • [36] Ambroziak U, Bednarczuk T, Przedlacki J et al, Bone metabolism and elements of metabolis syndrome in Young adults with CAH in chronic glucocorticoid treatment, ENDO 2009, Washington.
  • [37] Nongaki K., New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000; 43: 533-549
  • [38] Nowak A., Is congenital adrenal hyperplasia due to 21-hydroxylase deficiency deceptive disease? Management and differentiation of syndrome in adults. Proceeding of the Shevchenko Scientific Society Medical Sciences, 2017.
  • [39] Baron JJ, Baron J. Differential diagnosis of hirsutism in girls between 15-19 years old. Ginekologia Polska, 1993 May; 64(5): 267-9.
  • [40] Bauman A, Bauman CG. Virilizing adrenocortical carcinoma: Development in a patient with salt-losing congenital adrenal hyperplasia. JAMA. 1982 Dec 17; 248(23): 3140-1
  • [41] Charmandari E, Brook CG, Hindmarsh PC. Classic congenital adrenal hyperplasia and puberty. European journal of endocrinology. 2004 Nov 1; 151 (Suppl 3): U77-82.
  • [42] Malouf MA, Migeon CJ, Carson KA, Petrucci L, Wisniewski AB. Cognitive outcome in adult women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone Research in Paediatrics, 2006; 65(3): 142-150
  • [43] Małunowicz EM., Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in women with hyperandrogenic syndroms. Endokrynologia Ped 2008; 7: 9-18
  • [44] Miller WL. The adrenal cortex. In: Rudolph AM, Hoffman JIE (ed.). Pediatrics. Appleton & Lange, Norwalk 1991: 1584-1614
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-68fab627-95b6-4550-92ad-040cea486bd7
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.